Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines

被引:42
|
作者
Mancia, Giuseppe [1 ]
Kjeldsen, Sverre E. [2 ]
Kreutz, Reinhold [3 ]
Pathak, Atul [4 ]
Grassi, Guido [1 ]
Esler, Murray [5 ,6 ]
机构
[1] Univ Milano Bicocca, Milan, Italy
[2] Univ Oslo, Ullevaal Hosp, Dept Cardiol, Oslo, Norway
[3] Charite Univ Med Berlin, Inst Clin Pharmacol & Toxicol, Berlin, Germany
[4] Ctr Hosp Princesse Grace, Dept Cardiol, Monte Carlo, Monaco
[5] Baker Heart & Diabet Inst, Human Neurotransmitters Lab, Melbourne, Vic, Australia
[6] Monash Univ, Melbourne, Vic, Australia
关键词
antihypertensive drugs; beta-blockers; blood pressure; heart rate; hypertension; CHRONIC OBSTRUCTIVE PULMONARY; ELEVATED HEART-RATE; RANDOMIZED-TRIAL; ANTIHYPERTENSIVE DRUGS; ELDERLY-PATIENTS; NERVOUS-SYSTEM; INTERMITTENT CLAUDICATION; CARDIOVASCULAR MORBIDITY; MORTALITY; FAILURE;
D O I
10.1161/HYPERTENSIONAHA.122.19020
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Several hypertension guidelines have removed beta-blockers from their previous position as first-choice drugs for the treatment of hypertension. However, this downgrading may not be justified by available evidence because beta-blockers lower blood pressure as effectively as other major antihypertensive drugs and have solid documentation in preventing cardiovascular complications. Suspected inconveniences of beta-blockers such as increased risk of depression or erectile dysfunction may have been overemphasized, while patients with chronic obstructive pulmonary disease or peripheral artery disease, that is, conditions in which their use was previously restricted, will benefit from beta-blocker therapy. Besides, evidence that from early to late phases, hypertension is accompanied by activation of the sympathetic nervous system makes beta-blockers pathophysiologically an appropriate treatment in hypertension. Beta-blockers have favorable effects on a variety of clinical conditions that may coexist with hypertension, making their use either as specific treatment or as co-treatment potentially common in clinical practice. Guidelines typically limit recommendations on specific beta-blocker use to cardiac conditions including angina pectoris, postmyocardial infarction, or heart failure, with little or no mention of the additional cardiovascular or noncardiovascular conditions in which these drugs may be needed or preferred. In the present narrative review, we focus on multiple additional diseases and conditions that may occur and affect patients with hypertension, often more frequently than people without hypertension, and that may favor the choice of beta-blocker. Notwithstanding, beta-blockers represent an in-homogenous group of drugs and choosing beta-blockers with documented effect in prevention and treatment of disease is important for first choice in guidelines.
引用
收藏
页码:1153 / 1166
页数:14
相关论文
共 50 条
  • [1] European Society of Hypertension and European Society of Cardiology Guidelines and the Muted Enthusiasm for Home Blood Pressure Monitoring
    Doyle-Campbell, Courtney
    HYPERTENSION, 2014, 63 (02) : E5 - E5
  • [2] Harmonization of the American College of Cardiology/ American Heart Association and European Society of Cardiology/ European Society of Hypertension Blood Pressure/Hypertension Guidelines
    Whelton, Paul K.
    Carey, Robert M.
    Mancia, Giuseppe
    Kreutz, Reinhold
    Bundy, Joshua D.
    Williams, Bryan
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 80 (12) : 1192 - 1201
  • [3] Response to European Society of Hypertension and European Society of Cardiology Guidelines and the Muted Enthusiasm for Home Blood Pressure Monitoring
    Jennings, Garry L. R.
    Touyz, Rhian M.
    HYPERTENSION, 2014, 63 (02) : E6 - E6
  • [5] Comments on the guidelines (2018) of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) on the management of arterial hypertension
    Mahfoud, F.
    Boehm, M.
    Bongarth, C. M.
    Bosch, R.
    Schmieder, R. E.
    Schunkert, H.
    Stellbrink, C.
    Trenkwalder, P.
    Vonend, O.
    Weil, J.
    Kreutz, R.
    INTERNIST, 2019, 60 (04): : 424 - 430
  • [6] Prevalence of isolated nocturnal hypertension according to 2018 European Society of Cardiology and European Society of Hypertension office blood pressure categories
    Salazar, Martin R.
    Espeche, Walter G.
    Balbin, Eduardo
    Leiva Sisnieguez, Carlos E.
    Minetto, Julian
    Leiva Sisnieguez, Betty C.
    Maciel, Pablo M.
    Stavile, Rodolfo N.
    Carbajal, Horacio A.
    JOURNAL OF HYPERTENSION, 2020, 38 (03) : 434 - 440
  • [7] 2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC)
    Williams, Bryan
    Mancia, Giuseppe
    Spiering, Wilko
    Rosei, Enrico Agabiti
    Azizi, Michel
    Burnier, Michel
    Clement, Denis
    Coca, Antonio
    De Simone, Giovanni
    Dominiczak, Anna
    Kahan, Thomas
    Mahfoud, Felix
    Redon, Josep
    Ruilope, Luis
    Zanchetti, Alberto
    Kerins, Mary
    Kjeldsen, Sverre
    Kreutz, Reinhold
    Laurent, Stephane
    Lip, Gregory Y. H.
    McManus, Richard
    Narkiewicz, Krzysztof
    Ruschitzka, Frank
    Schmieder, Roland
    Shlyakhto, Evgeny
    Tsioufis, Konstantinos
    Aboyans, Victor
    Desormais, Ileana
    BLOOD PRESSURE, 2018, 27 (06) : 314 - 340
  • [8] Comments on the guidelines (2018) of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) on themanagement of arterial hypertension
    Mahfoud, F.
    Boehm, M.
    Bongarth, C. M.
    Bosch, R.
    Schmieder, R. E.
    Schunkert, H.
    Stellbrink, C.
    Trenkwalder, P.
    Vonend, O.
    Weil, J.
    Kreutz, R.
    KARDIOLOGE, 2019, 13 (01): : 17 - 23
  • [9] Special cases of high blood pressure: Guideline recommendations of the European Society of Cardiology and European Society of Hypertension [Besondere Bluthochdruckfälle: Leitlinienempfehlungen der European Society of Cardiology und European Society of Hypertension]
    Derer W.
    Dechend R.
    Der Kardiologe, 2014, 8 (5): : 419 - 428
  • [10] Guidelines 2007 Guidelines for the treatment of hypertension by the Committee for the drafting of the Guidelines of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC)
    Mancia, Giuseppe
    De Backer, Guy
    Dominiczak, Anna
    Cifkova, Renata
    Fagard, Robert
    Germano, Giuseppe
    Grassi, Guido
    Heagerty, Anthony M.
    Kjeldsen, Sverre E.
    Laurent, Stephane
    Narkiewicz, Krzysztof
    Ruilope, Luis
    Rynkiewicz, Andrzej
    Schmieder, Roland E.
    Boudier, Harry A. J. Struijker
    Zanchetti, Alberto
    GIORNALE ITALIANO DI CARDIOLOGIA, 2007, 8 (07) : 389 - 479